ABSTRACT
Objective To investigate the effect of thalidomide combined with targeted therapy of gefitinib on quality of life and survival in patients with advanced non-small cell lung cancer. Methods 90 cases with non-small cell lung cancer were selected in our hospital, according to the treatment were divided into observation group and control group, the observation group were treated by thalidomide combined with gefitinib treatment, patients in the control group received only gefitinib treatment, treatment effects was compared between the two groups, the remission rate, quality of life and survival were compared between two groups of patients. Results The effective rate of the observation group patients was 55.6%, compared with 33.3% in the control group, the difference was statistically significant (P<0.05), the life quality of the observation group of general health (general health, GH), physical functioning (PF), role –physical (RP), role-emotional (RE), mental health (MH), social functioning (SF), bodily pain (BP) and vitality (VT) were significantly better than the control group (P<0.05), there was no significant difference in 1, 2, 3, 4 years survival rate between two groups, while 5 years survival rate in observation group was higher than the control group(P<0.05). Conclusion Thalidomide combined with gefitinib targeted therapy is helpful to improve the quality of life and 5 years survival rate of non-small cell lung cancer.
ABSTRACT
Objective: To investigate genotype-phenotype changes between rs29230 in gamma-aminobutyric acid B receptor [GABBR1], rs1801278 in insulin receptor substrate-1 [IRS-1], and rs9902709 in hypocretin neuropeptide precursor [HCRT] and obstructive sleep apnea hypopnea syndrome [OSAHS] in Chinese Han individuals
Materials and Methods: A total of 130 patients with OSAHS and 136 age- and gendermatched healthy controls were enrolled in this study. A brief description of DNA extraction and genotyping is given. Multivariate unconditional logistic regression analysis adjusted for gender and age was used to estimate the associations of single nucleotide polymorphisms [SNPs] rs29230 [GABBR1], rs1801278 [IRS-1], and rs9902709 [HCRT] with OSAHS risk. Subgroup analysis was performed to evaluate differences in these SNPs among subgroups according to gender, body mass index [BMI], and severity of disease
Results: Genotype and allele frequencies of rs29230 were significantly different between cases and controls [p = 0.0205 and p = 0.0191, respectively; odds ratio = 0.493, 95% confidence interval = 0.271-0.896], especially for male patients [p = 0.0259 and p = 0.0202, respectively]. Subgroup analysis according to BMI also revealed a significant allele difference for rs29230 between cases and controls in the overweight subgroup [p = 0.0333]. Furthermore, allele and genotype frequencies of rs1801278 showed significant differences between cases and controls [p = 0.0488 and p = 0.0471, respectively]. How-ever, no association was observed between rs9902709 and OSAHS risk [p = 0.2762], and no differences were identified in other subgroups
Conclusion: In this study, there was an association between variants of rs29230 and rs1801278 and OSAHS risk in the Chinese Han population but not for rs9902709
ABSTRACT
Objective To study the changes of heart rate variability (HRV) and the effects of treatment with nasal continuous positive airway pressure (nCPAP) in elderly patients with sleep apnea/ hypopnea syndrome (SAHS). Methods SAHS patients and controls were examined by polysomnography(PSG) and dynamic cardiograph(DCG). Mean RR interval(Mean RRi), standard deviation of RR interval (SDRRi), low frequency(LF), high frequency(HF) and their ratio(LF/HF) were calculated. Results When compared with controls(847.9?113.8)ms vs (45.7?16.2) ms, there was significantly decrease in the Mean RRi and SDRRi in moderate, severe elderly patients and non-elderly SAHS patients(764.3?131.0)ms, (709.4?101.8)ms, (759.5?80.0)ms and (37.5?12.2)ms, (31.5?9.6)ms, (41.4?10.6)ms. There was statistical differences in LF, HF, and LF/HF between elderly and non-elderly severe SAHS (P